{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:09:29Z","timestamp":1792656569452,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Exper.Med."],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1007\/s10238-007-0145-8","type":"journal-article","created":{"date-parts":[[2008,1,10]],"date-time":"2008-01-10T17:47:56Z","timestamp":1199987276000},"page":"127-134","source":"Crossref","is-referenced-by-count":125,"title":["Uncovering Pandora\u2019s vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib"],"prefix":"10.1007","volume":"7","author":[{"given":"C.","family":"Porta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Paglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Imarisio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bonomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,3,16]]},"reference":[{"issue":"[Suppl8]","key":"145_CR1","first-page":"2","volume":"32","author":"J. Ajani","year":"2004","unstructured":"Ajani J, Allgood V (2004) Molecular mechanisms in cancer: what should clinicians know? Semin Oncol 32[Suppl 8]:2\u20134","journal-title":"Semin Oncol"},{"key":"145_CR2","unstructured":"\u2014 (2004) Managing patients through aggressive cancer therapies. ONS News 19[Suppl]:33\u201334"},{"key":"145_CR3","doi-asserted-by":"crossref","unstructured":"Escudier B, Szczylik C, Eisen T et al (2005) Randomized phase III trial of the Raf kinase and VEGFR inhibitor Sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Assoc Clin Oncol 23:Abs. 4510","DOI":"10.1200\/jco.2005.23.16_suppl.lba4510"},{"key":"145_CR4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B. Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125\u2013134","journal-title":"N Engl J Med"},{"key":"145_CR5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"R.J. Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 356:115\u2013124","journal-title":"N Engl J Med"},{"key":"145_CR6","doi-asserted-by":"crossref","unstructured":"Demetri GD, Van Oosterom AT, Blackstein M et al (2005) Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST. Proc Am Assoc Clin Oncol 23:Abs. 4000","DOI":"10.1200\/jco.2005.23.16_suppl.4000"},{"key":"145_CR7","doi-asserted-by":"crossref","first-page":"637","DOI":"10.3109\/07357909109039875","volume":"9","author":"R.M. Hansen","year":"1991","unstructured":"Hansen RM (1991) 5-Fluorouracil by protracted venous infusion: a review of recent clinical studies. Cancer Invest 9:637\u2013642","journal-title":"Cancer Invest"},{"key":"145_CR8","first-page":"1161","volume":"18","author":"W. Scheithauer","year":"2004","unstructured":"Scheithauer W, Blum J (2004) Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. Oncology (Huntingt) 18:1161\u20131168","journal-title":"Oncology (Huntingt)"},{"key":"145_CR9","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","volume":"13","author":"A. Trotti","year":"2003","unstructured":"Trotti A, Colevas AD, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176\u2013181","journal-title":"Semin Radiat Oncol"},{"key":"145_CR10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","volume":"6","author":"C. Robert","year":"2005","unstructured":"Robert C, Soria JC, Spatz A et al (2005) Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6:491\u2013500","journal-title":"Lancet Oncol"},{"key":"145_CR11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2340\/000155551773438","volume":"177","author":"J. Serup","year":"1992","unstructured":"Serup J (1992) A double-blind comparison of two creams containing urea as the active ingredient. Assessment of efficacy and side-effects by non-invasive techniques and a clinical scoring scheme. Acta Derm Venereol Suppl (Stockh) 177:34\u201343","journal-title":"Acta Derm Venereol Suppl (Stockh)"},{"key":"145_CR12","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1540-9740.2004.04056.x","volume":"3","author":"J. Bikowski","year":"2004","unstructured":"Bikowski J (2004) Hyperkeratosis of the heels: treatment with salicylic acid in a novel delivery system. Skinmed 3:350\u2013351","journal-title":"Skinmed"},{"key":"145_CR13","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2133.2004.06026.x","volume":"151","author":"W. Jacot","year":"2004","unstructured":"Jacot W, Bessis D, Jorda E et al (2004) Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumors. Br J Dermatol 151:238\u2013241","journal-title":"Br J Dermatol"},{"issue":"[Suppl12]","key":"145_CR14","first-page":"23","volume":"17","author":"R. Perez-Soler","year":"2003","unstructured":"Perez-Soler R (2003) Can rash associated with HER1\/EGFR inhibition be used as a marker of treatment outcome? Oncology (Huntingt) 17[Suppl 12]:23\u201328","journal-title":"Oncology (Huntingt)"},{"key":"145_CR15","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","volume":"23","author":"R. Perez-Soler","year":"2005","unstructured":"Perez-Soler R, Saltz L (2005) Cutaneous adverse effects with HER1\/EGFR-targeted agents: is there a silver lining? J Clin Oncol 23:5235\u20135246","journal-title":"J Clin Oncol"},{"key":"145_CR16","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.2002.20.1.110","volume":"20","author":"J. Albanell","year":"2002","unstructured":"Albanell J, Rojo F, Averbuch S et al (2002) Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20:110\u2013124","journal-title":"J Clin Oncol"},{"key":"145_CR17","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1038\/sj.jid.5700252","volume":"126","author":"A.T. Funding","year":"2006","unstructured":"Funding AT, Johansen C, Kragballe K et al (2006) Mitogenand stress-activated protein kinase 1 is activated in lesional psoriatic epidermis and regulates the expression of pro-inflammatory cytokines. J Invest Dermatol 126:1784\u20131791","journal-title":"J Invest Dermatol"},{"key":"145_CR18","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0002-9440(10)61213-8","volume":"167","author":"T.A. Wilgus","year":"2005","unstructured":"Wilgus TA, Matthies AM, Radek KA et al (2005) Novel function for vascular endothelial growth factor receptor-1 on epidermal keratinocytes. Am J Pathol 167:1257\u20131266","journal-title":"Am J Pathol"},{"key":"145_CR19","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1128\/AAC.47.11.3630-3633.2003","volume":"47","author":"T. Krakauer","year":"2003","unstructured":"Krakauer T, Buckley M (2003) Doxycycline is anti-inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines. Antimicrob Agents Chemother 47:3630\u20133633","journal-title":"Antimicrob Agents Chemother"},{"key":"145_CR20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/jac\/dkh519","volume":"55","author":"A. GW","year":"2005","unstructured":"Amsden GW (2005) Anti-inflammatory effects of macrolides \u2014 an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 55:10\u201321","journal-title":"J Antimicrob Chemother"},{"key":"145_CR21","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1055\/s-2002-35666","volume":"68","author":"A. Yagi","year":"2002","unstructured":"Yagi A, Kabash A, Okamura N et al (2002) Antioxidant, free radical scavenging and anti-inflammatory effects of aloesin derivatives in Aloe vera. Planta Med 68:957\u2013960","journal-title":"Planta Med"},{"key":"145_CR22","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.0105-1873.2005.00713.x","volume":"53","author":"N. Reider","year":"2005","unstructured":"Reider N, Issa A, Hawranek T et al (2005) Absence of contact sensitization to Aloe vera (L.) Burm. f. Contact Dermatitis 53:332\u2013334","journal-title":"Contact Dermatitis"},{"key":"145_CR23","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ctcp.2005.02.001","volume":"11","author":"W. Maddocks-Jennings","year":"2005","unstructured":"Maddocks-Jennings W, Wilkinson JM, Shillington D (2005) Novel approaches to radiotherapy-induced skin reactions: a literature review. Complement Ther Clin Pract 11:224\u2013231","journal-title":"Complement Ther Clin Pract"},{"key":"145_CR24","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1124\/jpet.103.052530","volume":"307","author":"K.G. Moss","year":"2003","unstructured":"Moss KG, Toner GC, Cherrington JM et al (2003) Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J Pharmacol Exp Ther 307:476\u2013480","journal-title":"J Pharmacol Exp Ther"},{"key":"145_CR25","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1096\/fj.00-0368com","volume":"15","author":"N.V. Botchkareva","year":"2001","unstructured":"Botchkareva NV, Khlgatian M, Longley BJ et al (2001) SCF\/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit. FASEB J 15:645\u2013658","journal-title":"FASEB J"},{"key":"145_CR26","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00008390-199510000-00002","volume":"5","author":"D. Luo","year":"1995","unstructured":"Luo D, Chen H, Searles G, Jimbow K (1995) Coordinated mRNA expression of c-Kit with tyrosinase and TRP-1 in melanin pigmentation of normal and malignant human melanocytes and transient activation of tyrosinase by Kit\/SCF-R. Melanoma Res 5:303\u2013309","journal-title":"Melanoma Res"},{"key":"145_CR27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0895-7061(02)03149-7","volume":"16","author":"D.C. Feldemen","year":"2003","unstructured":"Feldemen DC, Spencer CGC, Belgore FM et al (2003) Endothelial damage and angiogenesis in hypertensive patients. Relationship to cardiovascular risk factors and risk factor management. Am J Hypertens 16:11\u201320","journal-title":"Am J Hypertens"},{"issue":"[Suppl7]","key":"145_CR28","first-page":"S147","volume":"10","author":"H.A.J. Struijker Boudier","year":"1992","unstructured":"Struijker Boudier HAJ, Le Noble JLML, Messing MWJ et al (1992) The microcirculation and hypertension. J Hypertens 10[Suppl 7]:S147\u2013S156","journal-title":"J Hypertens"},{"key":"145_CR29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2174\/157016106775203126","volume":"4","author":"H. Nakashima","year":"2006","unstructured":"Nakashima H, Suzuki H, Ohtsu H et al (2006) Angiotensin II regulates vascular and endothelial dysfunction: recent topics of Angiotensin II type-1 receptor signaling in the vasculature. Curr Vasc Pharmacol 4:67\u201378","journal-title":"Curr Vasc Pharmacol"},{"key":"145_CR30","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1200\/JCO.2005.02.0503","volume":"24","author":"M.L. Veronese","year":"2006","unstructured":"Veronese ML, Mosenkis A, Flaherty KT et al (2006) 134 Mechanism of hypertension associated with BAY 43-9006. J Clin Oncol 24:1363\u20131369","journal-title":"J Clin Oncol"},{"key":"145_CR31","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1517\/14656566.5.4.893","volume":"5","author":"J. Cockcroft","year":"2004","unstructured":"Cockcroft J (2004) Nebivolol: a review. Expert Opin Pharmacother 5:893\u2013899","journal-title":"Expert Opin Pharmacother"},{"key":"145_CR32","first-page":"1449","volume":"161","author":"D. Baatar","year":"2002","unstructured":"Baatar D, Jones MK, Tsugawa K et al (2002) Esophageal ulceration triggers expression of hypoxia-inducible factor-1\u03b1 and activates vascular endothelial growth factor gene. Am J Physiol 161:1449\u20131457","journal-title":"Am J Physiol"},{"key":"145_CR33","doi-asserted-by":"crossref","first-page":"G1277","DOI":"10.1152\/ajpgi.00484.2002","volume":"285","author":"P. Rafiee","year":"2003","unstructured":"Rafiee P, Ogawa H, Heidemann J et al (2003) Isolation and characterization of human esophageal microvascular endothelial cells: mechanisms of inflammatory activation. Am J Physiol Gastrointest Liver Physiol 285:G1277\u20131292","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"145_CR34","doi-asserted-by":"crossref","first-page":"G665","DOI":"10.1152\/ajpgi.00238.2005","volume":"290","author":"Y. Fujiwara","year":"2005","unstructured":"Fujiwara Y, Higuchi K, Takashima T et al (2005) Roles of epidermal growth factor and Na+\/H+ exchanger-1 in esophageal epithelial defense against acid-induced injury. Am J Physiol Gastrointest Liver Physiol 290;G665\u2013673","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"[Suppl4]","key":"145_CR35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1046\/j.1365-2036.16.s4.11.x","volume":"16","author":"G.N. Tytgat","year":"2002","unstructured":"Tytgat GN (2002) Review article: treatment of mild and severe cases of GERD. Aliment Pharmacol Ther 16[Suppl 4]:73\u201378","journal-title":"Aliment Pharmacol Ther"},{"key":"145_CR36","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/S0140-6736(06)68932-0","volume":"367","author":"P. Moayyedi","year":"2006","unstructured":"Moayyedi P, Talley NJ (2006) Gastro-oesophageal reflux disease. Lancet 367:2086\u20132100","journal-title":"Lancet"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-007-0145-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10238-007-0145-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-007-0145-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T19:36:19Z","timestamp":1684179379000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10238-007-0145-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["145"],"URL":"https:\/\/doi.org\/10.1007\/s10238-007-0145-8","relation":{},"ISSN":["1591-8890","1591-9528"],"issn-type":[{"value":"1591-8890","type":"print"},{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}